Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults
- 1 March 2016
- journal article
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 20 (3) , 290-294
Abstract
Drug-resistant tuberculosis (DR-TB) is a growing public health problem, and for the first time in decades, new drugs for the treatment of this disease have been developed. These new drugs have prompted strengthened efforts in DR-TB clinical trials research, and there are now multiple ongoing and planned DR-TB clinical trials. To facilitate comparability and maximise policy impact, a common set of core research definitions is needed, and this paper presents a core set of efficacy and safety definitions as well as other important considerations in DR-TB clinical trials work. To elaborate these definitions, a search of clinical trials registries, published manuscripts and conference proceedings was undertaken to identify groups conducting trials of new regimens for the treatment of DR-TB. Individuals from these groups developed the core set of definitions presented here. Further work is needed to validate and assess the utility of these definitions but they represent an important first step to ensure there is comparability in clinical trials on multidrug-resistant TB.Keywords
This publication has 8 references indexed in Scilit:
- Advancing the portfolio of tuberculosis diagnostics, drugs, biomarkers, and vaccinesThe Lancet Infectious Diseases, 2014
- New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospectsThe Lancet Infectious Diseases, 2014
- Principles for designing future regimens for multidrug-resistant tuberculosisBulletin of the World Health Organization, 2013
- Patterns of Treatment Interruption among Patients with Multidrug-Resistant TB (MDR TB) and Association with Interim and Final Treatment OutcomesPLOS ONE, 2013
- Content analysis and thematic analysis: Implications for conducting a qualitative descriptive studyNursing & Health Sciences, 2013
- Time until Relapse in Tuberculosis Treatment Trials: Implication for Phase 3 Trial DesignAmerican Journal of Respiratory and Critical Care Medicine, 2012
- The origin of isolated positive cultures from the sputum of patients in four studies of short course chemotherapy in AfricaTubercle, 1980
- CLINICAL EVALUATION OF ETHAMBUTOL IN PULMONARY TUBERCULOSISAnnals of the New York Academy of Sciences, 1966